In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Opko Health (OPK – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.34.
Tenthoff covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Crispr Therapeutics AG, and Arrowhead Pharmaceuticals. According to TipRanks, Tenthoff has an average return of 3.5% and a 33.86% success rate on recommended stocks.
Currently, the analyst consensus on Opko Health is a Strong Buy with an average price target of $3.75, a 179.85% upside from current levels. In a report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $5.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Opko Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $265.42 million and a GAAP net loss of $19.64 million. In comparison, last year the company earned a revenue of $309.89 million and had a GAAP net loss of $101.65 million
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPK in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Opko Health (OPK) Company Description:
OPKO Health, Inc. engages in the provision of healthcare services. It operates through the Diagnostics and Pharmaceuticals segments. The Diagnostics segment comprises clinical laboratory operations which acquired through the Bio-Reference and point-of-care operations. The Pharmaceuticals segment includes the pharmaceutical operations acquired in Chile, Mexico, Ireland, Israel, and Spain; and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.
Read More on OPK:
- OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results
- Options Volatility and Implied Earnings Moves Today, November 06, 2023
- New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023
- Opko Health presents new data on RAYALDEE at Kidney Week 2023
- OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023
